Fig. 7.

Anti-TLR4 antibody treatment has minimal effect in the transfer model of chronic colitis. A: treatment schedule for anti-TLR4 antibody and isotype control during adoptive transfer model of colitis. CD4⁺CD62L⁺ T cells were injected ip into RAG1−/− mice at day 0 of week 1. Mice were then injected ip at the indicated time points with either anti-TLR4 antibody or isotype control and euthanized at the end of 5 wk. B: anti-TLR4 treatment does not result in significant clinical differences. Graph shows percent body weight change. Data represent the average ± SE of 2 independent experiments with a total of 18 mice (n = 9 for anti-TLR4 and n = 9 for isotype-treated mice). Top line represents normal growth of control RAG−/− mice that did not undergo T cell transfer (n = 4). C: histological assessment of colitis severity in anti-TLR4 antibody and isotype control-treated mice. Data represent the mean histological score ± SE for mice from 2 independent experiments (n = 4 for anti-TLR4 and n = 4 for isotype). Anti-TLR4-treated mice have slightly worse colitis on histology. D: representative microscopic pictures of H&E staining of colon sections from anti-TLR4 antibody and isotype control-treated mice.